{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-012240","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2023-04-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.440032+00:00","generated_at":"2026-06-17T04:15:02.230016+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Erasca announces departure of CMO Wei Lin, promotion of Shannon Morris as new CMO","bullets":["CMO Wei Lin resigned to pursue other opportunities; last day April 21, 2023, no disagreement cited.","Shannon Morris, former SVP Clinical Development, promoted to CMO effective April 10, 2023.","Dr. Morris brings 20+ years oncology experience; led Cosela NDA at G1 Therapeutics and Imfinzi BLA at MedImmune.","New employment terms: base salary $470,000, 40% target bonus, and option to purchase 375,000 shares vesting monthly.","Dr. Morris reclassified from Tier 2 to Tier 1 Covered Employee under Severance Plan."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-012240","json":"https://secwatch.observer/filing/0000950170-23-012240.json","markdown":"https://secwatch.observer/filing/0000950170-23-012240.md","text":"https://secwatch.observer/filing/0000950170-23-012240.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023012240/0000950170-23-012240-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023012240/eras-20230404.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T04:15:02.230016+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5908a29bac","claim":"Wei Lin resigned as Chief Medical Officer at Erasca, Inc..","evidence_excerpt":"On April 4, 2023, Wei Lin, M.D. notified Erasca, Inc. (the “Company”) of his decision to resign from his position as Chief Medical Officer of the Company to pursue other opportunities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023012240/0000950170-23-012240-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"7d564a383c","claim":"Shannon R. Morris was appointed as Chief Medical Officer at Erasca, Inc..","evidence_excerpt":"Effective as of April 10, 2023, Shannon R. Morris, M.D., Ph.D. has been promoted to the position of the Chief Medical Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023012240/0000950170-23-012240-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}